{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:03:31Z","timestamp":1790694211728,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"20","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.vaccine.2023.03.069","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T14:30:49Z","timestamp":1680705049000},"page":"3292-3300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021\u20132022"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5637-4613","authenticated-orcid":false,"given":"Toon","family":"Braeye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4695-4275","authenticated-orcid":false,"given":"Lucy","family":"Catteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9876-4150","authenticated-orcid":false,"given":"Ruben","family":"Brondeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joris A.F.","family":"van Loenhout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7787-9397","authenticated-orcid":false,"given":"Kristiaan","family":"Proesmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Van Oyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0162-2202","authenticated-orcid":false,"given":"Veerle","family":"Stouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Hubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4805-9242","authenticated-orcid":false,"given":"Matthieu","family":"Billuart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achille","family":"Djiena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mahieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naima","family":"Hammami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Van Cauteren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chlo\u00e9","family":"Wyndham-Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.03.069_b0005","doi-asserted-by":"crossref","unstructured":"Proesmans K, Hancart S, Braeye T, Klamer S, Robesyn E, Djiena A, et al. COVID-19 contact tracing in Belgium: main indicators and performance, January \u2013 September 2021. Arch Public Health. 2022 Apr 13;80(1):118.","DOI":"10.1186\/s13690-022-00875-6"},{"issue":"39","key":"10.1016\/j.vaccine.2023.03.069_b0010","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.1016\/j.vaccine.2021.08.060","article-title":"Vaccine effectiveness against infection and onwards transmission of COVID-19: Analysis of Belgian contact tracing data, January-June 2021","volume":"39","author":"Braeye","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.03.069_b0015","doi-asserted-by":"crossref","unstructured":"Braeye T, Catteau L, Brondeel R, van Loenhout J, Proesmans K, Cornelissen L, et al. VACCINE EFFECTIVENESS AGAINST ONWARD TRANSMISSION OF SARS-COV2-INFECTION BY VARIANT OF CONCERN AND TIME SINCE VACCINATION, BELGIAN CONTACT TRACING, 2021. Vaccine [Internet]. 2022 Apr 12 [cited 2022 Apr 17]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0264410X22004418.","DOI":"10.2139\/ssrn.4000559"},{"issue":"31","key":"10.1016\/j.vaccine.2023.03.069_b0020","doi-asserted-by":"crossref","first-page":"2100640","DOI":"10.2807\/1560-7917.ES.2021.26.31.2100640","article-title":"Vaccine effectiveness against SARS-CoV-2 transmission and infections among household and other close contacts of confirmed cases, the Netherlands, February to May 2021","volume":"26","author":"de Gier","year":"2021","journal-title":"Eurosurveillance"},{"issue":"8","key":"10.1016\/j.vaccine.2023.03.069_b0025","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMoa2116597","article-title":"Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants","volume":"386","author":"Eyre","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.069_b0030","doi-asserted-by":"crossref","unstructured":"Baker JM, Nakayama JY, O\u2019Hegarty M, McGowan A, Teran RA, Bart SM, et al. SARS-CoV-2 B.1.1.529 (Omicron) Variant Transmission Within Households \u2014 Four U.S. Jurisdictions, November 2021\u2013February 2022. Morb Mortal Wkly Rep. 2022 Mar 4;71(9):341\u20136.","DOI":"10.15585\/mmwr.mm7109e1"},{"issue":"10321","key":"10.1016\/j.vaccine.2023.03.069_b0035","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0140-6736(21)02844-0","article-title":"Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum","volume":"399","author":"Dejnirattisai","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.vaccine.2023.03.069_b0040","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/vaccines10050743","article-title":"Increased Receptor Affinity and Reduced Recognition by Specific Antibodies Contribute to Immune Escape of SARS-CoV-2 Variant Omicron","volume":"10","author":"Vogt","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2023.03.069_b0045","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa","volume":"15;376(6593):eabn4947","author":"Pulliam","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.03.069_b0050","article-title":"cited 2022 Feb 5","author":"Accorsi","year":"2022","journal-title":"Available from:"},{"key":"10.1016\/j.vaccine.2023.03.069_b0055","unstructured":"Sciensano\u2019s COVID-19 dashboard: genomic surveillance [Internet]. Available from: https:\/\/datastudio.google.com\/embed\/reporting\/c14a5cfc-cab7-4812-848c-0369173148ab\/page\/urrUC."},{"key":"10.1016\/j.vaccine.2023.03.069_b0060","article-title":"COVID-19 vaccines: key facts [Internet]","author":"Glanville","year":"2020","journal-title":"European Medicines Agency"},{"key":"10.1016\/j.vaccine.2023.03.069_b0065","unstructured":"Liu X, Munro APS, Feng S, Janani L, Aley PK, Babbage G, et al. Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial. J Infect [Internet]. 2022 Apr 9 [cited 2022 Apr 15]; Available from: https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0163445322002006."},{"key":"10.1016\/j.vaccine.2023.03.069_b0070","doi-asserted-by":"crossref","unstructured":"Puhach O, Adea K, Hulo N, Sattonnet P, Genecand C, Iten A, et al. Infectious viral load in unvaccinated and vaccinated individuals infected with ancestral, Delta or Omicron SARS-CoV-2. Nat Med. 2022 Apr 8;1\u20131.","DOI":"10.1101\/2022.01.10.22269010"},{"issue":"26","key":"10.1016\/j.vaccine.2023.03.069_b0075","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1056\/NEJMc2102507","article-title":"Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons","volume":"385","author":"Kissler","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2023.03.069_b0080","article-title":"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study","author":"Singanayagam","year":"2021","journal-title":"Lancet Infect Dis [Internet]"},{"issue":"5","key":"10.1016\/j.vaccine.2023.03.069_b0085","doi-asserted-by":"crossref","first-page":"e2213606","DOI":"10.1001\/jamanetworkopen.2022.13606","article-title":"Transmission and Infectious SARS-CoV-2 Shedding Kinetics in Vaccinated and Unvaccinated Individuals","volume":"5","author":"Jung","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.03.069_b0090","doi-asserted-by":"crossref","unstructured":"Regev-Yochay G, Amit S, Bergwerk M, Lipsitch M, Leshem E, Kahn R, et al. Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. Lancet Reg Health \u2013 Eur [Internet]. 2021 Aug 1 [cited 2022 Apr 26];7. Available from: https:\/\/www.thelancet.com\/journals\/lanepe\/article\/PIIS2666-7762(21)00127-7\/fulltext.","DOI":"10.1016\/j.lanepe.2021.100150"},{"issue":"9","key":"10.1016\/j.vaccine.2023.03.069_b0095","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.vaccine.2022.01.020","article-title":"Reducing the rates of household transmission: The impact of COVID-19 vaccination in healthcare workers with a known household exposure","volume":"40","author":"Passaretti","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.03.069_b0100","unstructured":"Lusvarghi S, Pollett SD, Neerukonda SN, Wang W, Wang R, Vassell R, et al. SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies. Sci Transl Med. 0(0):eabn8543."},{"issue":"1","key":"10.1016\/j.vaccine.2023.03.069_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/22221751.2021.2017757","article-title":"The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron","volume":"11","author":"Zhang","year":"2022","journal-title":"Emerg Microbes Infect"},{"issue":"209","key":"10.1016\/j.vaccine.2023.03.069_b0110","article-title":"SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity","volume":"1","author":"Pilz","year":"2022","journal-title":"Environ Res"},{"key":"10.1016\/j.vaccine.2023.03.069_b0115","doi-asserted-by":"crossref","unstructured":"Braeye T, Loenhout J van, Brondeel R, Stouten V, Hubin P, Billuart M, et al. COVID-19 Vaccine effectiveness against symptomatic infection and hospitalization in Belgium, July 2021-APRIL 2022 [Internet]. medRxiv; 2022 [cited 2022 May 28]. p. 2022.05.09.222746Available from: https:\/\/www.medrxiv.org\/content\/10.1101\/2022.05.09.22274623v1.","DOI":"10.1101\/2022.05.09.22274623"},{"issue":"6","key":"10.1016\/j.vaccine.2023.03.069_b0120","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3390\/v14061297","article-title":"Clinical Severity of SARS-CoV-2 Omicron Variant Compared with Delta among Hospitalized COVID-19 Patients in Belgium during Autumn and Winter Season 2021\u20132022","volume":"14","author":"Van Goethem","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.03.069_b0125","article-title":"Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data","volume":"20","author":"Michlmayr","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.vaccine.2023.03.069_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41564-021-01051-2","article-title":"Longitudinal analysis of antibody dynamics in COVID-19 convalescents reveals neutralizing responses up to 16 months after infection","volume":"7","author":"Yang","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.vaccine.2023.03.069_b0135","doi-asserted-by":"crossref","unstructured":"Muik A, Lui BG, Wallisch AK, Bacher M, M\u00fchl J, Reinholz J, et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine\u2013elicited human sera. Science [Internet]. 2022 Jan 18 [cited 2022 Feb 6]; Available from: https:\/\/www.science.org\/doi\/abs\/10.1126\/science.abn7591.","DOI":"10.1101\/2021.12.22.21268103"},{"issue":"6608","key":"10.1016\/j.vaccine.2023.03.069_b0140","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1126\/science.add2897","article-title":"T cell immunity to COVID-19 vaccines","volume":"377","author":"Wherry","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2023.03.069_b0145","doi-asserted-by":"crossref","unstructured":"Kotaki R, Adachi Y, Moriyama S, Onodera T, Fukushi S, Nagakura T, et al. SARS-CoV-2 Omicron-neutralizing memory B cells are elicited by two doses of BNT162b2 mRNA vaccine. Sci Immunol. 7(70):eabn8590.","DOI":"10.1126\/sciimmunol.abn8590"},{"key":"10.1016\/j.vaccine.2023.03.069_b0150","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo1303","article-title":"Understanding T cell responses to COVID-19 is essential for informing public health strategies","author":"Vardhana","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.vaccine.2023.03.069_b0155","doi-asserted-by":"crossref","unstructured":"Bates TA, McBride SK, Leier HC, Guzman G, Lyski ZL, Schoen D, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Sci Immunol [Internet]. 2022 Jan 25 [cited 2022 Jan 30]; Available from: https:\/\/www.science.org\/doi\/abs\/10.1126\/sciimmunol.abn8014.","DOI":"10.1126\/sciimmunol.abn8014"},{"issue":"12","key":"10.1016\/j.vaccine.2023.03.069_b0160","doi-asserted-by":"crossref","first-page":"e2031756","DOI":"10.1001\/jamanetworkopen.2020.31756","article-title":"Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis","volume":"3","author":"Madewell","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.vaccine.2023.03.069_b0165","article-title":"Household transmission of SARS-CoV-2 Omicron variant of concern subvariants BA.1 and BA.2 in Denmark","volume":"30;13(1):5760","author":"Lyngse","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.vaccine.2023.03.069_b0170","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1038\/s41467-022-33233-9","article-title":"Increased household transmission and immune escape of the SARS-CoV-2 Omicron compared to Delta variants","volume":"13","author":"Jalali","year":"2022","journal-title":"Nat Commun"},{"issue":"2","key":"10.1016\/j.vaccine.2023.03.069_b0175","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41591-022-02138-x","article-title":"Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave","volume":"29","author":"Tan","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2023.03.069_b0180","first-page":"1","article-title":"Comparative transmission of SARS-CoV-2 Omicron (B.1.1.529) and Delta (B.1.617.2) variants and the impact of vaccination: national cohort study, England","author":"Allen","year":"2023","journal-title":"Epidemiol Infect"},{"issue":"9","key":"10.1016\/j.vaccine.2023.03.069_b0185","doi-asserted-by":"crossref","first-page":"2100419","DOI":"10.2807\/1560-7917.ES.2022.27.9.2100419","article-title":"Seroprevalence of IgG antibodies against SARS-CoV-2 \u2013 a serial prospective cross-sectional nationwide study of residual samples, Belgium, March to October 2020","volume":"27","author":"Herzog","year":"2022","journal-title":"Eurosurveillance"},{"issue":"4","key":"10.1016\/j.vaccine.2023.03.069_b0190","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S1473-3099(22)00135-9","article-title":"Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults","volume":"22","author":"Vanshylla","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.03.069_b0195","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3390\/vaccines10010064","article-title":"Large-Scale Study of Antibody Titer Decay following BNT162b2 mRNA Vaccine or SARS-CoV-2 Infection","volume":"10","author":"Israel","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.vaccine.2023.03.069_b0200","doi-asserted-by":"crossref","unstructured":"Keshavarz B, Richards NE, Workman LJ, Patel J, Muehling LM, Canderan G, et al. Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection. Front Immunol [Internet]. 2022 [cited 2022 Apr 16];13. Available from: https:\/\/www.frontiersin.org\/article\/10.3389\/fimmu.2022.850987.","DOI":"10.3389\/fimmu.2022.850987"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003766?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23003766?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:27:51Z","timestamp":1759404471000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23003766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":40,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0264410X23003766"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.069","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vaccine effectiveness against transmission of alpha, delta and omicron SARS-COV-2-infection, Belgian contact tracing, 2021\u20132022","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}